biote (BTMD) Competitors $3.36 -0.10 (-2.89%) Closing price 04/3/2025 04:00 PM EasternExtended Trading$3.53 +0.17 (+5.06%) As of 04/3/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BTMD vs. GYRE, RCKT, BCAX, LENZ, CRON, COGT, PRTA, ABCL, ABUS, and AVBPShould you be buying biote stock or one of its competitors? The main competitors of biote include Gyre Therapeutics (GYRE), Rocket Pharmaceuticals (RCKT), Bicara Therapeutics (BCAX), LENZ Therapeutics (LENZ), Cronos Group (CRON), Cogent Biosciences (COGT), Prothena (PRTA), AbCellera Biologics (ABCL), Arbutus Biopharma (ABUS), and ArriVent BioPharma (AVBP). These companies are all part of the "pharmaceutical products" industry. biote vs. Gyre Therapeutics Rocket Pharmaceuticals Bicara Therapeutics LENZ Therapeutics Cronos Group Cogent Biosciences Prothena AbCellera Biologics Arbutus Biopharma ArriVent BioPharma Gyre Therapeutics (NASDAQ:GYRE) and biote (NASDAQ:BTMD) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, community ranking, earnings and risk. Which has stronger earnings & valuation, GYRE or BTMD? biote has higher revenue and earnings than Gyre Therapeutics. biote is trading at a lower price-to-earnings ratio than Gyre Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGyre Therapeutics$105.76M5.97-$92.93M$0.05134.80biote$197.19M0.93$3.32M$0.1818.72 Do insiders and institutionals have more ownership in GYRE or BTMD? 24.0% of Gyre Therapeutics shares are held by institutional investors. Comparatively, 21.7% of biote shares are held by institutional investors. 19.5% of Gyre Therapeutics shares are held by company insiders. Comparatively, 13.9% of biote shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts recommend GYRE or BTMD? biote has a consensus price target of $8.00, indicating a potential upside of 137.39%. Given biote's higher possible upside, analysts clearly believe biote is more favorable than Gyre Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gyre Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00biote 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer GYRE or BTMD? In the previous week, Gyre Therapeutics had 3 more articles in the media than biote. MarketBeat recorded 6 mentions for Gyre Therapeutics and 3 mentions for biote. Gyre Therapeutics' average media sentiment score of 0.11 beat biote's score of 0.00 indicating that Gyre Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gyre Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral biote 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is GYRE or BTMD more profitable? biote has a net margin of 5.20% compared to Gyre Therapeutics' net margin of -84.57%. biote's return on equity of -32.41% beat Gyre Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Gyre Therapeutics-84.57% -118.43% -71.97% biote 5.20%-32.41%22.26% Which has more risk & volatility, GYRE or BTMD? Gyre Therapeutics has a beta of 1.93, suggesting that its share price is 93% more volatile than the S&P 500. Comparatively, biote has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500. Does the MarketBeat Community believe in GYRE or BTMD? biote received 14 more outperform votes than Gyre Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformGyre TherapeuticsOutperform Votes1100.00% Underperform VotesNo VotesbioteOutperform Votes15100.00% Underperform VotesNo Votes Summarybiote beats Gyre Therapeutics on 8 of the 15 factors compared between the two stocks. Remove Ads Get biote News Delivered to You Automatically Sign up to receive the latest news and ratings for BTMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BTMD vs. The Competition Export to ExcelMetricbioteMedicinals & botanicals IndustryMedical SectorNASDAQ ExchangeMarket Cap$183.83M$1.17B$5.55B$7.49BDividend YieldN/AN/A5.35%4.04%P/E Ratio12.929.6222.9618.07Price / Sales0.935.83361.6786.81Price / Cash9.6010.4038.1634.64Price / Book-5.791.156.493.99Net Income$3.32M-$56.07M$3.21B$247.18M7 Day Performance-8.45%-7.13%-6.27%-6.41%1 Month Performance-20.75%-13.85%-0.55%-7.42%1 Year Performance-43.05%-48.39%6.15%-4.30% biote Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BTMDbiote3.4623 of 5 stars$3.36-2.9%$8.00+138.1%-43.1%$183.83M$197.19M12.92194Insider TradePositive NewsGYREGyre Therapeutics0.177 of 5 stars$7.72-15.3%N/A-60.4%$722.69M$105.76M154.4040Gap DownHigh Trading VolumeRCKTRocket Pharmaceuticals4.49 of 5 stars$6.67-12.1%$43.00+544.7%-78.1%$711.22MN/A-2.43240News CoverageGap DownHigh Trading VolumeBCAXBicara TherapeuticsN/A$13.03-2.8%$36.50+180.1%N/A$709.04MN/A0.0032Analyst RevisionGap DownLENZLENZ Therapeutics1.9088 of 5 stars$25.71+0.3%$41.67+62.1%+8.4%$708.13MN/A-5.39110Gap DownCRONCronos Group1.8764 of 5 stars$1.81+1.1%$3.00+65.7%-38.2%$692.38M$117.62M-13.92450Gap DownCOGTCogent Biosciences2.0777 of 5 stars$5.99-7.6%$14.43+140.9%-22.6%$681.96MN/A-2.4280Gap DownPRTAProthena3.1534 of 5 stars$12.38-5.8%$55.00+344.3%-53.3%$666.38M$135.16M-5.38130Gap DownABCLAbCellera Biologics1.9875 of 5 stars$2.23-3.5%$7.00+213.9%-52.3%$664.51M$28.83M-3.66500News CoveragePositive NewsABUSArbutus Biopharma1.4667 of 5 stars$3.49-0.3%$5.50+57.6%+20.2%$661.33M$6.17M-8.1290AVBPArriVent BioPharma1.2691 of 5 stars$18.49-2.4%$39.00+110.9%-6.5%$628.96MN/A-7.1940High Trading Volume Remove Ads Related Companies and Tools Related Companies Gyre Therapeutics Alternatives Rocket Pharmaceuticals Alternatives Bicara Therapeutics Alternatives LENZ Therapeutics Alternatives Cronos Group Alternatives Cogent Biosciences Alternatives Prothena Alternatives AbCellera Biologics Alternatives Arbutus Biopharma Alternatives ArriVent BioPharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BTMD) was last updated on 4/4/2025 by MarketBeat.com Staff From Our Partners“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTrump to unlock 15-figure fortune for America (May 3rd) ?We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men...Paradigm Press | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding biote Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share biote With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BTMD Stock Free BTMD Stock Alerts